BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

OBJECTIVES: BAY 81‐8973 (Kovaltry(®)), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1‐year LEOPOLD I trial. The LEOPOLD I extension evaluated long‐term efficacy and safety of BAY 81‐8973 prophylaxis. METH...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Haematol
Glavni autori: Mahlangu, Johnny, Lopez Fernandez, Maria Fernanda, Santagostino, Elena, Lalezari, Shadan, Tseneklidou‐Stoeter, Despina, Beckmann, Horst, Church, Nikki
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383510/
https://ncbi.nlm.nih.gov/pubmed/32112434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13402
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items